PLSE Stock Price, Pulse Biosciences Inc Quote, Chart

Market Summary

USD7.32+0.07

Delayedas of 30 Apr 2024, 03:04 pm

0.97%

PLSE Stock Price

View Fullscreen

PLSE RSI Chart

PLSE Valuation

Market Cap

400.4M

Price/Earnings (Trailing)

-9.49

Price/Sales (Trailing)

686.15

EV/EBITDA

-8.54

Price/Free Cashflow

-12.07

PLSE Price/Sales (Trailing)

PLSE Profitability

Operating Margin

100.00%

EBT Margin

-6030.00%

Return on Equity

-95.15%

Return on Assets

-71.36%

Free Cashflow Yield

-8.28%

PLSE Fundamentals

PLSE Revenue

PLSE Earnings

Earnings (TTM)

-42.2M

Earnings Growth (Yr)

-29.75%

Earnings Growth (Qtr)

-12.94%

Breaking Down PLSE Revenue

52 Week Range

3.889.69

(Low)(High)

Last 7 days

5.8%

Last 30 days

-16.8%

Last 90 days

-20.2%

Trailing 12 Months

12.6%

How does PLSE drawdown profile look like?

PLSE Financial Health

Current Ratio

6.76

PLSE Investor Care

Shares Dilution (1Y)

46.90%

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	0	0	0	0
2022	1.9M	2.1M	1.6M	700.0K
2021	0	0	682.0K	1.4M
2020	0	607.0K	326.0K	0
2019	0	0	0	0

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pulse Biosciences Inc

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Dec 12, 2023	duggan robert w	bought	164,691	9.15	17,999	-
Dec 11, 2023	duggan robert w	bought	843,504	9.36	90,118	-
Dec 08, 2023	duggan robert w	bought	1,112,900	9.54	116,656	-
Dec 07, 2023	duggan robert w	bought	687,890	9.19	74,852	-
Dec 06, 2023	duggan robert w	acquired	59,101	5.95	9,933	-
Dec 06, 2023	duggan robert w	bought	750,286	9.06	82,813	-
Dec 05, 2023	duggan robert w	bought	616,636	9.34	66,021	-
Dec 04, 2023	duggan robert w	acquired	430,099	10.66	40,347	-
Dec 04, 2023	duggan robert w	bought	280,260	10.38	27,000	-
Dec 01, 2023	duggan robert w	bought	413,592	9.07	45,600	-

Which funds bought or sold PLSE recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 25, 2024	Bank of New York Mellon Corp	reduced	-10.52	-205,114	359,505	-%
Apr 25, 2024	Lindbrook Capital, LLC	new	-	1,359	1,359	-%
Apr 25, 2024	SIMPLEX TRADING, LLC	reduced	-11.05	-154,000	265,000	-%
Apr 23, 2024	AMALGAMATED BANK	reduced	-66.65	-15,000	5,000	-%
Apr 23, 2024	BENDER ROBERT & ASSOCIATES	sold off	-100	-126,378	-	-%
Apr 23, 2024	CGC Financial Services, LLC	new	-	1,158	1,158	-%
Apr 22, 2024	MetLife Investment Management, LLC	new	-	111,445	111,445	-%
Apr 19, 2024	Westside Investment Management, Inc.	reduced	-5.9	-138,187	280,115	0.07%
Apr 17, 2024	GRIFFIN ASSET MANAGEMENT, INC.	added	15.68	-561,962	2,615,790	0.31%
Apr 05, 2024	CWM, LLC	new	-	-	-	-%

Are Funds Buying or Selling PLSE?

Are funds buying PLSE calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own PLSE

No. of Funds

Unveiling Pulse Biosciences Inc's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Dec 15, 2023	duggan robert w	68.8%	-	SC 13D/A
Dec 04, 2023	duggan robert w	67.8%	-	SC 13D/A
May 11, 2023	duggan robert w	68.7%	3,690,488	SC 13D/A
Jun 13, 2022	duggan robert w	62.1%	2,675,480	SC 13D/A
Jul 02, 2021	duggan robert w	51.2%	15,196,495	SC 13D/A
May 11, 2021	duggan robert w	45.6%	12,142,715	SC 13D/A
Feb 16, 2021	appel peter a	4.75%	1,205,065	SC 13G/A
Jun 17, 2020	duggan robert w	47.2%	12,100,284	SC 13D/A

Recent SEC filings of Pulse Biosciences Inc

View All Filings

Date Filed	Form Type	Document
Apr 25, 2024	S-3/A	S-3/A
Apr 23, 2024	S-3/A	S-3/A
Apr 23, 2024	DEFA14A	DEFA14A
Apr 23, 2024	DEF 14A	DEF 14A
Apr 15, 2024	S-3/A	S-3/A
Apr 08, 2024	EFFECT	EFFECT
Apr 03, 2024	S-3	S-3
Mar 28, 2024	S-3	S-3
Mar 28, 2024	8-K	Current Report
Mar 28, 2024	10-K	Annual Report

Peers (Alternatives to Pulse Biosciences Inc)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.1B	40.1B	-5.62%	-2.90%	32.52	4.64	-8.12%	-17.45%
BDX	67.4B	19.5B	-5.66%	-11.68%	53.7	3.46	4.02%	-22.04%
ALGN	22.9B	3.9B	-7.04%	-6.30%	51.44	5.93	3.42%	23.09%
BAX	20.6B	14.8B	-4.91%	-14.77%	7.77	1.39	2.12%	209.17%
MID-CAP
ATR	9.5B	3.5B	1.73%	23.52%	30.36	2.68	6.16%	35.06%
HSIC	9.4B	12.3B	-3.30%	-9.63%	22.56	0.76	-2.44%	-22.68%
BIO	8.1B	2.7B	-19.88%	-38.53%	-12.7	3.03	-4.68%	82.43%
XRAY	6.4B	4.0B	-7.53%	-26.81%	-47.32	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.96%	16.48%	-560.62	9.29	33.86%	89.83%
PDCO	2.3B	6.6B	-5.97%	-4.09%	12.04	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.99%	-14.73%	-1.99	0.42	7.73%	-1066.14%
ANIK	379.2M	166.7M	2.24%	1.21%	-4.59	2.28	6.67%	-456.34%
ANGO	233.1M	324.0M	-0.85%	-30.05%	-1.21	0.72	-3.19%	-337.41%
APYX	48.5M	52.3M	2.94%	-58.82%	-2.59	0.93	17.61%	19.28%
AEMD	3.6M	3.7M	-18.45%	260.53%	-0.29	0.96	5.77%	8.23%

Pulse Biosciences Inc News

Latest updates

Pulse Biosciences Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)												(In Thousands)
Description	(%) Q/Q	2023Q4	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2020Q3	2020Q2	2020Q1	2019Q3	2019Q2
Revenue	-	-	-	-	265,000	444,000	844,000	574,000	9,000	21,000	78,000	218,000	290,000
Cost Of Revenue	-100.0%	-	1,291,000	8,400,000	1,344,000	909,000	-	727,000	-	-	-	-	-
Costs and Expenses	43.5%	12,533,000	8,736,000	18,025,000	14,279,000	17,717,000	16,254,000	14,847,000	12,905,000	-	-	-	-
Operating Expenses	-	-	-	-	-	-	-	-	12,905,000	11,354,000	11,950,000	11,964,000	11,649,000
S&GA Expenses	83.3%	4,734,000	2,582,000	3,088,000	3,787,000	4,498,000	5,301,000	4,256,000	4,191,000	3,999,000	4,074,000	5,606,000	5,146,000
R&D Expenses	90.5%	7,799,000	4,095,000	4,517,000	5,458,000	6,769,000	5,658,000	6,460,000	6,968,000	5,870,000	6,181,000	6,192,000	6,337,000
EBITDA Margin	27.5%	-60.48	-83.46	-40.95	-29.95	-34.04	-44.06	-73.38	-	-	-	-	-
Interest Expenses	-	-	-	-	-	-	-	-	9,000	21,000	78,000	218,000	290,000
Income Taxes	-	-	-	-	-	-	-	-	-	-	-	-	-
Earnings Before Taxes	-29.7%	-11,933,000	-9,197,000	-18,039,000	-13,996,000	-17,273,000	-	-	-	-	-	-	-
EBT Margin	27.9%	-60.30	-83.58	-40.99	-29.93	-34.02	-43.96	-73.10	-	-	-	-	-
Net Income	-29.7%	-11,933,000	-9,197,000	-18,039,000	-13,996,000	-17,273,000	-15,416,000	-14,282,000	-12,896,000	-11,333,000	-11,872,000	-11,746,000	-11,359,000
Net Income Margin	27.9%	-60.30	-83.58	-41.68	-28.66	-33.29	-43.96	-90.90	-	-	-	-	-
Free Cashflow	14.8%	-6,825,000	-8,006,000	-10,694,000	-12,841,000	-15,873,000	-12,828,000	-13,507,000	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet																					(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Assets	-10.3%	59.00	66.00	75.00	70.00	78.00	88.00	41.00	40.00	54.00	67.00	80.00	81.00	41.00	50.00	58.00	32.00	42.00	49.00	57.00	63.00	71.00
Current Assets	-12.2%	45.00	52.00	60.00	55.00	62.00	71.00	24.00	22.00	37.00	49.00	62.00	62.00	22.00	30.00	39.00	16.00	26.00	36.00	45.00	53.00	60.00
Cash Equivalents	-11.9%	44.00	50.00	59.00	54.00	61.00	69.00	15.00	13.00	29.00	42.00	47.00	60.00	12.00	7.00	38.00	8.00	7.00	10.00	11.00	9.00	51.00
Inventory	-	-	-	-	-	-	1.00	8.00	7.00	6.00	4.00	3.00	1.00	-	-	-	-	-	-	-	-	-
Net PPE	-7.3%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	3.00	2.00	2.00	2.00	2.00	2.00	3.00	3.00	3.00	3.00	2.00	2.00	2.00	2.00
Goodwill	0%	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00	3.00
Liabilities	7.2%	15.00	14.00	14.00	81.00	80.00	81.00	17.00	19.00	19.00	20.00	20.00	60.00	18.00	17.00	16.00	10.00	11.00	8.00	7.00	4.00	4.00
Current Liabilities	23.5%	7.00	5.00	6.00	7.00	6.00	7.00	8.00	9.00	9.00	10.00	10.00	9.00	8.00	6.00	5.00	3.00	4.00	4.00	3.00	3.00	3.00
Shareholder's Equity	-14.9%	44.00	52.00	61.00	-	-2.25	6.00	23.00	21.00	36.00	47.00	60.00	20.00	23.00	33.00	42.00	22.00	31.00	41.00	50.00	59.00	66.00
Retained Earnings	-3.7%	-336	-324	-314	-304	-294	-285	-267	-253	-236	-220	-206	-191	-172	-158	-145	-134	-122	-108	-97.15	-85.80	-75.72
Additional Paid-In Capital	1.1%	381	377	375	294	292	292	291	274	272	268	266	212	195	191	188	156	153	150	147	145	142
Shares Outstanding	0.3%	55.00	55.00	55.00	38.00	37.00	37.00	31.00	30.00	30.00	30.00	26.00	26.00	23.00	-	-	-	-	-	-	-	-
Float	-	-	-	124	-	-	-	24.00	-	-	-	179	-	-	-	135	-	-	-	154	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Cashflow From Operations	35.3%	-6,782	-10,487	-9,202	-6,570	-7,965	-10,632	-12,822	-15,594	-12,694	-13,350	-16,366	-11,687	-9,255	-8,549	-7,939	-9,622	-9,196	-7,965	-9,694	-7,330	-6,308
Share Based Compensation	86.0%	3,344	1,798	1,143	896	748	723	1,713	2,007	3,611	1,577	2,448	6,965	2,389	2,648	2,412	2,626	3,548	2,679	2,699	2,361	2,350
Cashflow From Investing	-87.0%	-43.00	-23.00	-16.00	-39.00	-41.00	-62.00	-19.00	-279	-134	-157	-95.00	7,949	14,212	-22,572	8,081	10,323	6,525	6,554	12,551	-35,731	6,219
Cashflow From Financing	-62.6%	804	2,149	13,867	-432	-17.00	65,058	14,963	-65.00	-549	8,072	4,004	51,158	436	426	29,759	264	-	201	-613	494	44,861

Get Full Access to Grufity – and Unlimited Downloads

Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.

Try For Just $1.99

PLSE Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Revenues:
Total revenues	$ 0	$ 700
Cost and expenses:
Cost of revenues	0	11,944
Research and development	27,797	20,839
Sales and marketing	0	12,019
General and administrative	15,777	13,955
Total cost and expenses	43,574	58,757
Loss from operations	(43,574)	(58,057)
Other income (expense):
Interest income (expense), net	1,364	(448)
Total other income (expense)	1,364	(448)
Loss from operations, before income taxes	(42,210)	(58,505)
Income tax benefit	0	0
Net loss	(42,210)	(58,505)
Comprehensive loss	$ (42,210)	$ (58,505)
Net loss per share:
Basic and diluted net loss per share (in dollars per share)	$ (0.88)	$ (1.72)
Weighted average shares used to compute net loss per common share — basic and diluted (in shares)	48,038	33,935

PLSE Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets:
Cash and cash equivalents	$ 44,365	$ 61,139
Prepaid expenses and other current assets	963	1,008
Total current assets	45,328	62,147
Property and equipment, net	1,528	1,961
Intangible assets, net	1,886	2,551
Goodwill	2,791	2,791
Right-of-use assets	7,256	8,062
Other assets	365	365
Total assets	59,154	77,877
Current liabilities:
Accounts payable	1,836	1,573
Accrued expenses	3,814	2,595
Lease liability, current	1,058	896
Related party note payable, current	0	917
Total current liabilities	6,708	5,981
Lease liability, less current portion	8,086	9,144
Related party note payable, less current	0	65,000
Total liabilities	14,794	80,125
Commitments and contingencies (Note 13)
Stockholders’ equity:
Preferred stock, $0.001 par value; authorized – 50,000 shares; no shares issued and outstanding	0	0
Common stock, $0.001 par value; authorized – 500,000 shares; issued and outstanding – 55,144 shares and 37,235 shares at December 31, 2023 and 2022, respectively	55	37
Additional paid-in capital	381,220	292,420
Accumulated other comprehensive income (loss)	0	0
Accumulated deficit	(336,915)	(294,705)
Total stockholders’ equity (deficit)	44,360	(2,248)
Total liabilities and stockholders’ equity	$ 59,154	$ 77,877

About Pulse Biosciences Inc

Pulse Biosciences, Inc. operates as a novel bioelectric medicine company. It offers CellFX System, a tunable, software-enabled, and console-based platform that delivers nano second duration pulses of electrical energy to non-thermally clear targeted cells while sparing adjacent non-cellular tissue to treat a various medical condition by using its Nano-Pulse Stimulation technology. The company was formerly known as Electroblate, Inc. and changed its name to Pulse Biosciences, Inc. in December 2015. The company was incorporated in 2014 and is headquartered in Hayward, California.

WEBSITE	pulsebiosciences.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	61

Pulse Biosciences Inc Frequently Asked Questions

What is the ticker symbol for Pulse Biosciences Inc? What does PLSE stand for in stocks?

PLSE is the stock ticker symbol of Pulse Biosciences Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulse Biosciences Inc (PLSE)?

As of Mon Apr 29 2024, market cap of Pulse Biosciences Inc is 400.38 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of PLSE stock?

You can check PLSE's fair value in chart for subscribers.

What is the fair value of PLSE stock?

You can check PLSE's fair value in chart for subscribers. The fair value of Pulse Biosciences Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pulse Biosciences Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for PLSE so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pulse Biosciences Inc a good stock to buy?

The fair value guage provides a quick view whether PLSE is over valued or under valued. Whether Pulse Biosciences Inc is cheap or expensive depends on the assumptions which impact Pulse Biosciences Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for PLSE.

What is Pulse Biosciences Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Mon Apr 29 2024, PLSE's PE ratio (Price to Earnings) is -9.49 and Price to Sales (PS) ratio is 686.15. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. PLSE PE ratio will change depending on the future growth rate expectations of investors.